An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries
Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides
Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes
Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients
Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals
Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics
CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era
Contemporary costs of HIV healthcare in the HAART era
Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study
Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants
Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy
Antiretroviral treatment is a behavioural intervention: but why?
The role of the health system in HIV treatment-as-prevention
Hepatic safety and tolerability in the maraviroc clinical development program
Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
Raltegravir-induced cerebellar ataxia
HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6
Seroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception?